Last reviewed · How we verify

Memorial Healthcare System — Portfolio Competitive Intelligence Brief

Memorial Healthcare System pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cathflo Activase Cathflo Activase marketed
Talc Slurry Pleurodesis Talc Slurry Pleurodesis marketed Sclerosing agent Oncology / Pulmonology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Boston Scientific Corporation · 1 shared drug class
  2. Chinese University of Hong Kong · 1 shared drug class
  3. Gulab Devi Hospital · 1 shared drug class
  4. Imperial College London · 1 shared drug class
  5. Medical University of Vienna · 1 shared drug class
  6. UPECLIN HC FM Botucatu Unesp · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Memorial Healthcare System:

Cite this brief

Drug Landscape (2026). Memorial Healthcare System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/memorial-healthcare-system. Accessed 2026-05-16.

Related